Why Monopar Therapeutics And EyePoint Pharma Are Trading Higher Today

Monopar Therapeutics MNPR shares are trading higher Thursday after Roth Capital initiated coverage on the stock with a Buy rating and a price target of $49 per share.

Monopar Therapeutics is a U.S. clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.

Monopar Therapeutics shares were trading up 31.82% to $8.70 at the time of publication. The stock has a 52-week high of $20.50 and a 52-week low of $4.28.

EyePoint Pharmaceuticals EYPT shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and a price target of $22 per share. The company also announced the dosing of the first patient in its EYP-1901 trial.

EyePoint Pharmaceuticals is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. 

EyePoint Pharmaceuticals shares were trading up 10.70% to $10.86 at the time of publication. The stock has a 52-week high of $21 and a 52-week low of 44 cents.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!